Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma

NCT07303283 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

218

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma (NPC)
Locoregionally Advanced Nasopharyngeal Carcinoma
Adjuvant Therapy

Interventions

DRUG: Becotatug Vedotin
DRUG: capecitabine

Sponsor

Kai Hu

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]